

44

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number	10/507180
Filing Date	Sept. 9, 2004
First Named Inventor	Marie Pierre T.M.M.G. DE BETHUNE
Group Art Unit	1621
Examiner Name	Jennifer Cho
Attorney Docket Number	TIP28USPCT

[illegible]

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Translation	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
/JC/		EP	0 628 555	A1	BAYER AG	12-14-1994	No	
/JC/		FR	1.557.887		SOCIÉTÉ RHODIACETA	01-5-1968	No	
/JC/		WO	03/004458	A1	BIOVIT-RUM AB	01-16-2003	No	
/JC/		WO	91/05761	A1	UNIROYAL CHEMICAL LTD.	05-02-1991	No	
/JC/		WO	95/05170	A1	WARNER-LAMBERT COMPANY	02-23-1995	No	
/JC/								

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete If Known

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/507180
Filing Date	Sept. 9, 2004
First Named Inventor	Marie Pierre T.M.M.G. DE BETHUNE
Group Art Unit	
Examiner Name	
Attorney Docket Number	TIP28USPCT

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation	T ²
/JC/		M. HASEGAWA, et al., "Novel Napthalene Derivatives as Inhibitors of Human Immunoglobulin E Antibody Production", J. Med. Chem. (1997), 40, pp. 395-407.	No	
/JC/		J. MATYSIAK, et al., "In vitro inhibition properties of a new group of thiobenzanilides in relation to yeasts", European Journal of Pharmaceutical Sciences 10 (2000) 119-123.	No	
/JC/		J. MILTON, et al., "BIARYL ACIDS: NOVEL NON-NUCLEOSIDE INHIBITORS OF HIV REVERSE TRANSCRIPTASE TYPES 1 AND 2", Bioorganic & Medicinal Chemistry Letters 8 (1998) pp. 2623-2628.	No	
/JC/		V.B. OZA, et al., "Synthesis and Evaluation of Anthranilic Acid-Based Transthyretin Amyloid Fibril Inhibitors", Bioorganic & Medicinal Chemistry Letters 9 (1999) pp. 1-6.	No	
/JC/		A. VARNAVAS, et al., "Anthranoyl-anthranilic acid: a template for the development of a new class of cholecystokinin receptor ligands", Pharmazie 51 (1996) pp. 697-700.		

Examiner Signature	/Jennifer Cho/	Date Considered	08/15/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.